About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, January 22th, 2013

The QualityStocks
Daily Stock List


Talon Therapeutics, Inc. (TLON)

SmarTrend Newsletters, Real Pennies, and PennyTrader Publisher reported earlier on Talon Therapeutics, Inc. (TLON), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, Talon Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes new and differentiated cancer therapies. Their lead product candidate is Marqibo® (vinCRIStine sulfate LIPOSOME injection). In addition to Marqibo®, the Company has additional pipeline opportunities. Some, like Marqibo®, have the potential to improve delivery, enhance the therapeutic benefits of well-characterized, proven chemotherapies, and enable high potency dosing without increased toxicity.  Founded in 2002, Talon Therapeutics is based in South San Francisco, California.

Marqibo® is a new, targeted, nanoparticle-encapsulated, cancer therapeutic. The specific design of it is to improve patient outcomes by combining the potential for enhanced efficacy with the potential for reduced toxicity. Marqibo® consists of vincristine sulfate, a potent vinca alkaloid anti mitotic, encapsulated in the aqueous core of proprietary, sphingomyelin-based liposomes called Optisomes™. This distinct formulation has undergone development to facilitate high-concentration, targeted drug delivery and predictable, first-order, continuous drug release kinetics.

Talon's product pipeline includes Menadione Topical Lotion. This is a topical compound for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitor anti-cancer treatment. Furthermore, Talon has their Brakiva™ (topotecan liposomes injection, OPTISOME™) product. This is a novel, targeted, nanoparticle-encapsulated, anti-cancer compound for small cell lung and ovarian cancers. Additionally, the Company has their Alocrest™ (vinorelbine liposomes injection, OPTISOME™) product. This is a novel, targeted, nanoparticle-encapsulated, anti-cancer compound for lung and breast cancers.

Talon Therapeutics announced in August 2012 that Marqibo® received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. This indication is based on overall response rate. Marqibo® has received orphan drug designation for the treatment of ALL from the FDA and from the European Medicines Agency (EMA). Talon Therapeutics intends to submit a Marketing Authorization Application to the EMA this calendar year.

This month, Talon Therapeutics announced that their Board authorized a review of strategic alternatives. The Company has engaged Goldman Sachs to provide financial advisory services. The review of strategic alternatives may lead to a possible transaction, including the merger, business combination, or sale of the Company. The Company has made no decision to enter into a transaction at this time.

Talon Therapeutics, Inc. (TLON), closed Tuesday at trading session at $0.60, up 3.45%, on 15,250 volume with 7 trades. The average volume for the last 60 days is 65,371 and the stock's 52-week low/high is $0.40/$1.83.

Norsat International, Inc. (NSATF)

MicroCap Gems reported earlier on Norsat International, Inc. (NSATF), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCBB, Norsat International, Inc. is a leading provider of innovative communication solutions that enable the transmission of data, audio and video for challenging applications and environments. In addition, through their Norsat Power Solutions segment, the Company is a provider of power conversion and energy storage solutions for the communications, transportation and resource sectors. Norsat International has their headquarters in Richmond, British Columbia. They maintain a presence in the U.S., the UK, Switzerland, Italy, and Germany.

The Company serves global customers primarily through three business units. These are Sinclair Technologies, Satellite Solutions and Microwave Products. Norsat International is continuing to focus on implementing a business model that will serve to add a recurring revenue stream by offering a range of services, broaden the portfolio of products and services, actively recruit and cultivate reseller channel partners, and diversify their base of customers to include non-defense customers.

Norsat International's products and services include leading-edge product design and development, production, distribution and infield support and service of portable ground station satellite terminals, antennas, Radio Frequency (RF) conditioning products, microwave components, maritime-based satellite terminals and remote network connectivity solutions.

In 2012, Norsat was granted Final Acceptance with the NATO Communications and Information Agency (NATO) for their custom-designed dual Ku-band and X-band portable satellite terminals.

Additionally, the Company released a Satellite Locator application for iPhone on the App Store in June of 2012. The application enables users to locate geostationary satellites on a mobile phone from anywhere in the world. It can be used to assess obstructions and assist in pointing satellite ground terminals, including Norsat' International's ultra-portable GLOBETrekker™ and Rover™ systems. In late October 2012, Norsat announced the launch of their Satellite Locator App for Android.

In November 2012, the Company announced the launch of Global-VSAT™, an equipment and global airtime services package that takes advantage of the Norsat MarineLink™ line of maritime VSAT terminals. The package is available through flexible lease and purchase options. It will provide Norsat International's maritime customers with a complete end-to-end communications solution. This includes terminals, modems, airtime, installation, and technical support.

Recently, Norsat won multiple business awards for export success and leadership. The Company won the BC Export Award for Advancing Technology & Innovation, as President & CEO, Dr. Amiee Chan, won WXN Canada's Most Powerful Women: Top 100™ Award.

Norsat International, Inc. (NSATF), closed at $0.59, up 2.61%, on 600 volume with 2 trades. The average volume for the last 60 days is 40,888 and the stock's 52-week low/high is $0.346/$0.565.

Internet Media Services, Inc. (ITMV)

SmallCapVoice and Nebula Stocks reported previously on Internet Media Services, Inc. (ITMV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Internet Media Services, Inc. is a diversified digital media company whose shares trade on the OTC Bulletin Board. The Company operates their branded websites within discrete vertical business channels or markets. This allows allowing them to utilize cross-promotion marketing activities between their websites within a channel. Founded in 2007, Internet Media Services has their headquarters in Santa Monica, California.

The Company is primarily focusing on creating, acquiring and collaborating with companies with customer acquisition- customer relationship management solutions. In addition, the Company is interested in information technology/content acquisition opportunities. This is whether the content is informational, educational, or entertaining.

Internet Media Services' four building blocks encompass Acquiring, Building, Marketing, and Monetizing. For acquisitions, they acquire undervalued Web properties in defined vertical channels. For building, they construct scalable Internet applications and top performing Web properties. For marketing, they use their expertise in Internet marketing techniques to increase traffic to their properties. For monetizing, with increased traffic to their Web properties, they utilize their knowledge to convert visitors to paying visitors.

On October 8, 2009, Internet Media Services completed their first acquisition in the legal vertical market. This was via the purchase of the assets and the assumption of certain liabilities of LegalStore.com. LegalStore.com is an Internet based company that primarily sells legal supplies and legal forms.

They subsequently leveraged this acquisition through the creation and development of SimplyProspects.com. This is a proprietary "auction-based marketplace" involved in the lead-sale industry in the legal field, and in many other key niche markets. These include elective medical; home reconstruction; health and medicine; leisure and travel, and others.

Internet Media Services released SimplyProspects.com in July 2011 as part of a six-month beta program. At the end of this six-month period in December 2011, the Company (based on the feedback obtained during the beta program) decided to develop the service further before releasing the service into production.

Internet Media Services, Inc. (ITMV), closed Tuesday's trading session at $0.025, up 212.50%, on 594,119 volume with 29 trades. The average volume for the last 60 days is 1,484 and the stock's 52-week low/high is $0.008/$0.095.

Trio Gold Corp. (TGK.V)

We are highlighting Trio Gold Corp. (TGK.V), here at the QualityStocks Daily Newsletter.

Trio Gold Corp. is a junior mining company whose shares trade on the TSX Venture Exchange.  The Company's commitment is to the exploration, analysis, and evaluation of precious mineral properties on a global scale. Trio Gold's interests include gold, silver, and copper. The Company became a public corporation in 1987. Trio Gold has their corporate headquarters in Calgary, Alberta.

The Company searches for premier reserves and deposits with significant mining and market value. Trio Gold has their Rodeo Creek Property in the Carlin Trend, in the State of Nevada. They own a 100 percent interest in this property, which is situated at the north end of the Carlin Trend in Elko County, Nevada, and approximately 56 km northwest of the town of Carlin. The property consists of 29 contiguous mineral claims covering an area of 547 acres (221 hectares).

The Rodeo Creek Property is 1.5 kilometers northwest of Barrick Gold Corp.'s Storm deposit, 3 kilometers northwest of their South Arturo discovery, 8 kilometers northwest of the famed Meikle Mine and 5 kilometers northwest of Centerra Gold's REN property. Previous drilling on the property confirms that Rodeo Creek exhibits the geological and alteration features common to many Carlin deposits; namely NW & NE control-faults, and halos of decalcification and silicification alteration within the highly prospective Popovich Formation, host to over 85 percent of all deposits along the Carlin Trend.

The Rodeo Creek property is considered to have very high potential for the discovery of one or more gold deposits similar to those currently undergoing mining elsewhere on this Trend. Five geochemically anomalous target areas are outlined for further exploration and exploration permits are current.

In January of last year, Trio Gold reported that they signed an Option Agreement with Coastal Pacific Mining Corp. and the property vendor to earn a 50 percent interest in the Hotstone Gold property in Ontario, Canada. The Hotstone property consists of 4 claim units located within Greenlaw Township, 50 km southeast of Chapleau, and 130 km west-southwest of Timmins.

Hotstone is located on trend west of the newly emerging West Porcupine Gold camp. This camp includes the producing Timmins Mine of Lake Shore Gold Corp.

Trio Gold Corp. (TGK.V), closed Tuesday's trading session at $0.02, up 100.00%, on 983,450 volume. The stock's 52-week low/high is $0.01/$0.04.

X-Factor Communications Holdings, Inc. (XFCH)

Today we are highlighting X-Factor Communications Holdings, Inc. (XFCH), here at the QualityStocks Daily Newsletter.

X-Factor Communications Holdings, Inc., by way of their wholly owned subsidiary, X-Factor Communications, LLC, provides interactive digital media network software and services in the United States. The X-Factor Digital Media Network Platform is the Company's cloud-based digital signage, web and mobile solution. It undergoes delivery as a software-as-a-service (SaaS) and under a software license model. This enables X-Factor Communications' customers to build simple yet scalable advertising and corporate digital media networks.

The Company's solutions address the fast expanding digital media needs of their corporate, public venue, education and government sector customers. Founded in 2005, X-Factor Communications Holdings lists on the OTC Bulletin Board. The Company has their corporate headquarters in South Hackensack, New Jersey.

X-Factor Communications' webcasting solution is a live and on-demand multimedia distribution product. It delivers rich media content, desktop signage and emergency messaging to mobile and Web devices. The Company sells their software and services throughout the U.S.

X-Factor Communications' X-Factor Platform components include dscp:// - Digital Signage Control Portal. This is a digital signage software application that allows users to deploy and manage digital signage services. Components also include DMAX (Digital Media Advertising Exchange) and Storefront Advertising Portals that are ecommerce portals that support public and private advertising sales, campaign creation, order fulfillment, and billing.

In addition, components include dmcp:// - Digital Media Control Portal and Webcasting, a live and on-demand multimedia distribution product that delivers media content, desktop signage, and emergency messaging to mobile and Web devices. On top of these, components additionally include Media Service Bureau and Creative Services. These provide a family of professional grade digital media services, including digital media application development, content creation, and management services.

Over the past two years, the Company has benefited from limited direct sales efforts and sales referrals from Cisco Systems, Inc. and some of the larger integrators/reseller sales channels in the marketplace. X-Factor Communications believes their company now has positioning to implement an aggressive marketing campaign to increase the sales volume through these sales channels. Moreover, the Company has introduced stand-alone solutions to the marketplace that they plan to market along with their partner oriented product portfolio.

X-Factor Communications Holdings, Inc. (XFCH), closed Tuesday's trading session at $1.01, up 34.67%, on 200 volume with 2 trades. The average volume for the last 60 days is 10,356 and the stock's 52-week low/high is $0.75/$1.25.

Maxwell Resources, Inc. (MAXE)

Today we are highlighting Maxwell Resources, Inc. (MAXE), here at the QualityStocks Daily Newsletter.

Incorporated in the State of Nevada on November 17, 2010, Maxwell Resources, Inc. engages in natural resource mining and exploration. The Company has acquired certain gold, silver, iron ore, copper and coal interests in New Mexico. The Company formerly went by the name Mericol, Inc. They changed their name to Maxwell Resources, Inc. in September of 2012. Maxwell Resources has their corporate headquarters in Las Vegas, Nevada.

Effective July 27, 2012, pursuant to a Contract for sale with Sun River Energy, Inc. (Sun River), Maxwell Resources acquired certain gold, silver, iron ore, copper and coal interests in Colfax County, New Mexico. As additional consideration for the purchase of the mineral assets, the Company was also granted a three-year option to acquire a five percent working interest (WI) in any oil and/or gas (including coalbed methane) wells drilled on any properties owned by Sun River in New Mexico.

Maxwell Resources' goal is the exploration of the Raton Basin for potential energy and valuable metals reserves. This basin in northern New Mexico has potential as a premier source of coking coal, gold, silver and other rare minerals. The Company plans to prove up on the coal, gold/silver and other rare minerals within the basin, pinpointing the sites that will result in the largest return on investment (ROI).

The Raton Basin is situated in what once was the largest land grant in New Mexico history – namely, the Maxwell Land Grant. Today, in addition to mining operations, the land grant is home to the 33,000-acre Colin Neblatt State Wildlife Area. This includes the Cimarron Canyon State Park, purchased by the State of New Mexico in the early 1950s. The Raton Basin is between Dawson and Elizabethtown, New Mexico, approximately three hours north of Albuquerque and one hour north of Taos.

The United States Geological Survey (USGS) has studied the region; the basin contains potentially $3.4 billion in metallurgical (coking) coal, according to 1991 USGS estimates - based on: 51 million tons coking coal (per USGS 1991) x 44 percent est. recovery factor (in situ to washed) x $150 /ton (=$250/ton coking coal - $100/ton est. mining & shipping cost).

A 2005 study indicates there could be even more high-grade coal than the USGS previously estimated. (Pillmore 1991, USGS Bulletin, No. 1972) (Hoffman Report, 2005).

Maxwell Resources, Inc. (MAXE), closed Tuesday's trading session at $0.39, down 2.99%, on 500,758 volume with 43 trades. The average volume for the last 60 days is 105,733 and the stock's 52-week low/high is $0.40/$1.15.

Monster Offers (MONT)

SmarTrend Newsletters, OTC Picks, Video Penny Stocks, Penny Stocks VIP, PennyStockScholar, and OTCtipReporter reported earlier on Monster Offers (MONT), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Monster Offers (soon to be renamed "Monster Mobile Marketing") is a leading Daily Deal analytics provider and aggregator as well as mobile advertising company. The Company connects daily deals from multiple sites in local communities across the United States and Canada. Monster Offers collects and publishes thousands of daily deals and allows consumers to organize these deals by geography or product categories, or to personalize the results using keyword search.

The Company has their headquarters in Laguna Niguel, California. Monster Offers is a public company recently created from the merger of Ad Shark, Inc., an innovative leader in mobile marketing advertising consulting, with and into Monster Offers. The Company's shares trade on the OTC Bulletin Board.

Monster Offers focuses on providing easy-to-use solutions to un-met market needs in the Daily Deal industry. These include Mobile & One-click Banking (P2P (person-to-person) Payment & Settlement Services, Redemption Programs, Loyalty Programs, and Pre-Paid Debit Cards). These also include Personalized & Relevant Daily Deal Aggregation as well as Daily Deal Analytics & Reporting Services.

With Monster Offers, a user can obtain the best deals from Groupon, LivingSocial and other popular sites daily. The Company's website MonsterOffers.com is also customizable so users use the aforementioned keyword search and Zip Code radius features to view the deals that fit their interests and location, making them more relevant to an individual.

Through their Ad Shark division, Monster Offers develops and implements mobile advertising sales efforts through building a strong media and advertising delivery system.  Their innovative approach involves integrating traditional internet advertising with optimized media and cutting-edge ad delivery methods, all tailored specifically for the applicable Smart Device, OS or screen resolution platform.

Last week, Monster Offers announced their strategic alliance with Hozio - an online marketing agency that provides boutique advertising and promotional services to small and medium-sized businesses. Under the parties' agreement, Monster Offers will extend local search engine optimization (LSEO) service offerings to their clients. Through this new arrangement, Monster Offers will be offering unique marketing to those businesses that have previously relied on more traditional forms of paper-based advertising such as Yellow Pages, newspaper advertising and direct mail.

Monster Offers (MONT), closed Tuesday's session at $0.881, up 33.48%, on 646 volume with 1 trade. The average volume for the last 60 days is 6,834 and the stock's 52-week low/high is $0.25/$4.50.

Swingplane Ventures, Inc. (SWVI)

We are highlighting Swingplane Ventures, Inc. (SWVI), here at the QualityStocks Daily Newsletter.

Incorporated in the State of Nevada on June 24, 2010, and based in Santiago, Chile, Swingplane Ventures' plan is to engage in activities in the mining industry. On October 15, 2012, they entered into an assignment agreement with Mid Americas Corp. (Mid Americas). Under the terms of the assignment agreement, Swingplane Ventures will be assigned all of the rights under an option agreement between Mid Americas and Gunter Stromber and Elsa Dorila Durate Horta (the Vendors) whereby Mid Americas has the rights to acquire 75 percent of certain mining concessions in Chile.

In November 2012, the Company announced that they appointed a new Director to oversee the Chilean operations. On November 2, 2012, they appointed Mr. Johannes Lindorfer to the Board of Directors. Mr. Lindorfer has more than 20 years experience in management, planning and participating in several geotechnical, geological, metallurgical and other work in different areas of the mining sector.

Additionally, in November, Swingplane Ventures announced that they would be opening offices in Chile to undertake operations of their new project. The Algarrobo Property consists of 21 "Angela" and 11 "Roble" tenures, consisting of 6,161 ha located approximately 35 km east of the port city of Caldera. The Property is within a regionally extensive, iron-enriched metallogenic belt, part of a Mesozoic volcanic arc extending from southern Peru through northern Chile.

Mining operations completed to date, on both the Property and immediately adjacent tenures have resulted in approximately 35 mines. These range from near surface workings to operations that are more extensive, extending several hundred meters below surface.

Today, Swingplane Ventures announced that the Company has renegotiated their assignment agreement regarding the acquisition of certain mining concessions in Chile. Under the terms of the original assignment agreement entered into on October 15, 2012, they were assigned the rights to an option agreement held by Mid Americas Corp. This was for, among other terms, the issuance of 300,000,000 shares of the common stock of the Company; 10,000,000 shares were to be included in a registration statement to be filed by the Company before closing.

Under the terms of the newly negotiated agreement, Swingplane Ventures will acquire all of the issued and outstanding shares of Mid Americas. This is in exchange for the issuance of 100,000,000 shares of common stock of the Company and 5,000,000 shares of preferred stock of the Company. All other terms of the original acquisition agreement are to be included in this acquisition agreement.

Swingplane Ventures, Inc. (SWVI), closed Tuesday's trading session at $0.1702, down 3.33%, on 15,649,797 volume with 305 trades. The average volume for the last 60 days is 8,816 and the stock's 52-week low/high is $0.15/$0.23.


The QualityStocks
Company Corner


VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.79, up 8.22%, on 13,500 volume with 7 trades. The stock’s average daily volume over the past 60 days is 1,429, and its 52-week low/high is $0.06/$3.10.

VistaGen Therapeutics, Inc. was proud to report that CEO, Shawn K. Singh, will be presenting on the company's progress and many unique opportunities to apply their Human Clinical Trials in a Test Tube™ stem cell technology platform for drug rescue, predictive toxicology, and drug metabolism screening at the Ninth Annual Equity Conference hosted by Noble Financial Capital Markets. A live audio/video webcast, along with presentation materials, will be made available on the company's website (www.vistagen.com). The presentation is scheduled for 12:30 pm EST on Wednesday, January 23, at the Hard Rock Hotel in Hollywood, Florida.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference

VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium

VistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D™

TNI BioTech, Inc. (TNIB)

The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $8.45, down 0.59%, on 12,850 volume with 33 trades. The stock’s average daily volume over the past 60 days is 26,953, and its 52-week low/high is $0.72/$10.38.

TNI BioTech, Inc. reported a change in the company's lineup today with the appointment of broad-spectrum finance pro, Peter Aronstam, to the CFO position. Former CFO, Christopher Pearce, will be moving to the COO slot where his extensive corporate operations experience will remain on-hand through the transition and potential up-listing of TNIB to a fully reporting company (Form 10 to be filed with SEC in the next 45 days). With over 30 years in accounting, banking, finance, and international trade across several growth and performance-driven enterprises in senior finance roles, Aronstam will be vital to TNIB through a period set to be marked by significant growth and acquisition.

TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.

The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.

The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer

TNI BioTech, Inc. Company Blog

TNI BioTech, Inc. News:

TNI BioTech, Inc. Announces Appointment of New CFO

TNI BioTech, Inc. Acquires the Exclusive Rights to Low Dose Naltrexone and Other Opioid Antagonists for the Treatment of Inflammatory and Ulcerative Diseases of the Bowel

TNI BioTech to Present at 6th Annual OneMedForum San Francisco 2013


The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.0118, up 2.61%, on 1,443,507 volume with 12 trades. The stock’s average daily volume over the past 60 days is 811,690, and its 52-week low/high is $0.0013/$0.015.

VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.

The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.

VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.

The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer

VIASPACE, Inc. Company Blog

VIASPACE, Inc. News:

VIASPACE Giant King Grass Energy Crop Growing in Hawaii

VIASPACE CEO Invited to Speak At EUEC2013 Conference and Company to Feature GiantKing™ Grass in Exhibit Hall

St. Croix Giant King Grass-Fueled Electric Power Plant Design Approved by Public Services Commission

Viscount Systems, Inc. (VSYS)

The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.099, up 1.02%, on 114,200 volume with 10 trades. The stock’s average daily volume over the past 60 days is 53,601, and its 52-week low/high is $0.0069/$0.13.

Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.

Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.

Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.

Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer

Viscount Systems, Inc. Company Blog

Viscount Systems, Inc. News:

Viscount Systems Awarded New U.S. Government Contract

Viscount Systems To Secure Canadian Hotel Chain

Viscount Awarded Contract to Secure New Mexico School District

TNI BioTech, Inc. (TNIB) to File Audited Financial Statements, Appoints New Chief Financial Officer

TNI BioTech, a biotech company working to combat chronic, life-threatening diseases through the activation modulating the body’s immune system, today announced the appointment of Mr. Peter Aronstam as the company’s Chief Financial Officer. He is replacing Mr. Christopher Pearce, who will now serve as the Chief Operating Officer.

“Mr. Aronstam’s broad-based experience as a finance professional in private and public companies gives him a solid platform for the job of Chief Financial Officer of TNI BioTech,” stated Ms. Noreen Griffin, Chief Executive Officer. “We welcome Peter and look forward to working with him as part of the TNI BioTech management team.”

“Mr. Pearce has done a tremendous job as Chief Financial Officer. He joined TNI BioTech nine months ago at its onset and has been a great asset to our operations throughout our period of growth and acquisition. I am pleased that Mr. Pearce will be available to assist TNI BioTech during the transition between CFOs, and will also assume the position as Chief Operating Officer. I also wish to thank him for his ongoing commitment to TNI BioTech,” added Ms. Griffin.

According to today’s press release, TNI BioTech made these changes in connection with the retention of Liggett, Vogt & Webb P.A. This accounting firm has been engaged to provide professionally audited financial statements for inclusion in a Form 10 filing with the SEC in approximately 45 days. This form is essential for TNI BioTech to become a fully reporting company.

Encompassing more than three decades of experience in accounting, finance, banking, international trade, and law to TNI BioTech, Mr. Aronstam’s career is noted by a progression of senior finance roles with growth and performance-driven enterprises, from startup technology and Internet companies to small service providers ($50 million) to very large international manufacturers ($25 billion) and global banks.

Peter has advised and/or served as CFO in both publicly held and privately owned businesses since 1978. These include startup venture-capital-backed entrepreneurial companies; manufacturing, technology, and service companies; and corporate and international banking. Other roles included human resources (HR) and Information Technology (IT) functions along with raising more than $500 million in debt and equity for his companies and their customers.

For more information on TNI BioTech, visit www.TNIBioTech.com

VistaGen Therapeutics, Inc. (VSTA) Scheduled to Present at Noble Financial Capital Markets 9th Annual Equity Conference

Today before the opening bell, VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism screening, told investors that Shawn K. Singh, CEO of VistaGen, will be stepping into the spotlight at Noble Financial Capital Markets’ Ninth Annual Equity Conference.

Mr. Singh’s presentation will provide a comprehensive overview of the company’s progress and unique opportunities to apply its stem cell technology platform, Human Clinical Trials in a Test Tube™, for drug rescue, predictive toxicology, and drug metabolism screening. He will present at 12:30 pm EST on Wednesday, January 23, 2013, at the Hard Rock Hotel in Hollywood, Florida.

Those who wish to access the presentation materials as well as tune-in remotely via a live audio and video webcast should visit VistaGen’s website atwww.vistagen.com and Noble Financial’s website at www.noblefcm.com. Investors and analysts should register approximately 10 minutes before the start of the presentation to ensure timely access.

Let us hear your thoughts: VistaGen Therapeutics, Inc. Message Board

Viscount Systems Inc. (VSYS) Revolutionizes Security with Visionary Leadership

Viscount Systems, worldwide provider of access control and security products, has launched breakthrough technology that reduces security system hardware costs by up to 90% while significantly increasing functionality. Their big idea is to transfer facility security control functions from the traditional and costly hardware-oriented environment to a software and communications oriented platform. In additions to radically reducing costs, the revolutionary approach opens the door to new innovations simply not possible with standard electronic hardware systems. In addition, Viscount is considered the only real public investment vehicle in this space, representing a major market opportunity.

To drive and maintain such technological leadership, and maximize its value in the marketplace, requires management that is both visionary and practical, with a comprehensive knowledge of the global security industry:

• Dennis Raefield joined Viscount’s board in October 2011 and was later appointed to the COO position in December 2012. He brings extensive operating experience as the past President of the Honeywell Access Systems division, which operates at a $100 million annual revenue scale. His prior experience is rooted in the integration of large security systems, including being president of Pinkerton Systems Integration (now known as Securitas).

• Shayne Bates is the latest addition to the advisory team. Shayne has a long and documented history as a thought leader in the unification of physical and logical access control. He has emphasized Active Directory in his approach and has worked closely with Microsoft developing cloud strategy. His recent paper “Cloud Computing and Software-as-a-Service for Security Professionals” has played a role in defining the entire space.

• Ron Martin, also a member of Viscount’s advisory board, is known throughout the security industry as a thought leader in Identity Management and Physical Access Control systems. Ron regularly contributes to standards publications published by the National Institute of Standards and Technology, ASIS International, and the Security Industry Association. Ron was a major contributor to the U.S. Government’s Federal Identity, Credentialing and Access Management (ICAM) Roadmap.

• Paul Brisgone joined Viscount’s Board of Directors in December 2011 after 34 years at ADT, most recently as the VP of the Federal Systems Division, which grew dramatically from a small beachhead to over $150 million in revenue with a technical and support staff of 200. He has exactly the right experience, in the right market, with the right customers, and against the right competitors, to be extremely valuable to the company.

• Robert Liscouski joined Viscount’s board in September 2011 and brings expertise in security and IT. He was the first Assistant Secretary for the US Department of Homeland Security, running the $500 million Infrastructure Protection initiative for DHS. He’s been a homicide detective, a diplomat with the US State Department, and Head of Information Assurance for the Coca-Cola company. He is a partner in Secure Strategy Group.

• Paul Goldenberg joined the board in October 2011 and brings considerable experience, knowledge, and rapport with governments and agencies. He has a long and distinguished career in the criminal justice system, and was recognized with an appointment to the Homeland Security Advisory Council by Janet Napolitano in 2010.

For additional information, visit www.Viscount.com

Pluristem Therapeutics, Inc. (PSTI) Reports Latest Developments at Industry Conference

Pluristem Therapeutics, a leading developer of placenta-based cell therapies, announced that its senior scientists will present updated developments relating to the company’s proprietary 3D cell expansion technology at the Scale-Up and Manufacturing of Cell-Based Therapies II Conference in San Diego, California, which is being held January 21-23, 2013. These innovations will be implemented in Pluristem’s new state-of-the-art manufacturing facility for expansion of placental-derived mesenchymal-like Adherent Stromal Cells (ASCs).

The following presentations will be made by Pluristem’s team:

• “Bioreactors in Cell Therapy, the Advantages of High-Throughput Culturing Technologies and the Downstream Challenges” – Ohad Karnieli PhD, MBA and VP of Development at Pluristem, will present Pluristem’s new production line and demonstrate how the company has utilized high-throughput culturing to solve many of the problems related to the mass production of ASCs. Dr. Karnieli’s presentation will be made available at the company’s website .

• “From Gene Expression to In Vivo Models – Characterization and Potential Therapeutic Properties of Placenta Derived Mesenchymal-Like Adherent Stromal Cells” – Eytan Abraham, PhD and Product Innovation Research Manager, will address the specific changes that occur in gene regulation and protein secretion when ASCs are grown in a 3D culturing phase and the biological changes and therapeutic advantages of implementing this technology in the mass expansion of ASCs use.

Pluristem Therapeutics, a leading developer of placenta-based cell therapies, has a robust patent and patent applications portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. Pluristem is focusing on the development of PLX (PLacental eXpanded) cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.

For more information, visit www.pluristem.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





The Best Newsletters



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251